TXG Stock 10x Genomics, Inc.
US · NasdaqGSLast in our picks 2026-10-11 — not in the current list; analysis below is from that screen
Single-cell genomics leadership and improving innovation cycle offer high upside despite execution risk.
Future value: $67.47 (-16.35%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Barclays doubled target to $110 and maintained Overweight.
- ▸Above 50-day MA (+17.99%)
- ▸Above 200-day MA — long-term uptrend
- ▸Near 52-week high (75.8% of range) — strength
- ▾Trading above its price target — limited upside
Is TXG a buy right now?
Trend: TXG is trading above the 50-day average (+0.74%), RSI 57 — neutral momentum, with a 3-month return of +55.66%.
Valuation & quality: 10x Genomics, Inc. trades on forward P/E 955.3, price-to-book 11.56; fundamentals show net margin -12.2%, return on equity -9.4%, revenue growth -12.7% year on year.
Analyst consensus: 14 analysts have a mean 12-month price target of $77.50 (+5.8% vs the last close; range $50.00 – $110.00), consensus rating “buy”.
Our screen: BUY (score 3) — Single-cell genomics leadership and improving innovation cycle offer high upside despite execution risk.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -7.90% | +3.90% | +28.40% | +35.40% | +23.30% | +32.10% | +44.70% | -18.90% |
Fundamentals
Analyst price target
Technical signals
About 10x Genomics, Inc.
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.
Sector: Healthcare · Industry: Medical Devices · United States · 1,178 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.